Chokri Ben Lamine/LinkedIn
Jun 12, 2026, 16:14
Chokri Ben Lamine: EHA26 – SCD Curative Therapy Pathway
Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:
“EHA26 – SCD Curative Therapy Pathway
EHA-SWG and EBMT-HWP joint recommendations highlight who should be considered for:
- Allogeneic HCT
- Cell and gene therapy
in sickle cell disease
Key clinical logic:
- Confirm HbSS and severe HbSβ⁰ genotype
- Assess for severe clinical presentation
- If HLA-matched family donor is available, proceed to allo-HCT assessment
- If no matched donor is available and eligibility criteria are met, assess for gene therapy at a transplant center.
Practical message:
Curative therapy in SCD is becoming algorithm-driven, but still needs expert individualized review:
- genotype
- disease severity
- donor availability
- age
- regulatory and scientific updates
- patient-centered risk–benefit discussion
Session: Optimising the transplant process in haemoglobinopathies
Chair: Ben Carpenter”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Nov 10, 2026, 08:43Rufiga Shari Abidin: Multi Organ Complications Detailed in COVID 19 Vaccine Adverse Event Study
-
Nov 10, 2026, 08:36Bahram Alamdary Badlou: Why Jak Inhibitors Demand Careful Monitoring In Chronic Inflammation Treatment?
-
Nov 10, 2026, 08:16Uyiekpen Ima-Edomwonyi: Why Autoimmune Inflammation Demands Early Vigilance?
-
Nov 10, 2026, 06:20Vida Shafti: Can AI Help Us Predict Thrombosis before it Happens in Assisted Reproduction?
-
Nov 10, 2026, 06:11Michaël Prüfer: Treatment of Varicose Veins with Laser Endoveineux Total
-
Nov 10, 2026, 05:55Sandhya Selvakumar: Guide to Stroke Classification and Rehabilitation
-
Nov 9, 2026, 22:47Avirup Guha: Early Immune Responses to Androgen Deprivation Therapy and Coronary Plaque Progression
-
Nov 9, 2026, 22:42Angela Forsyth: Joining Novo Nordisk as Medical Liaison for the Ohio Valley Region
-
Nov 9, 2026, 22:36Vladimir Otasevic: Presenting Thromboprophylaxis and Treatment of VTE in Patients With Malignancy